"Primary Mitochondrial Myopathies Pipeline"The therapeutic landscape for Primary Mitochondrial Myopathies (PMM) is evolving rapidly, with novel approaches emerging to address the debilitating effects ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies ...
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies ...
IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (RPHM), a pharmaceutical company focused on the development and commercialization of therapies for patients with rare ...
IRVINE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for ...
Early-onset IBM challenges age-centric diagnostic criteria, with symptoms appearing in patients younger than 46. Younger IBM patients show a higher rate of mitochondrial DNA mutations, indicating ...
- Data presented at Mitochondrial Medicine Therapeutic Development (MMTD) annual conference demonstrated ARCUS’ ability to efficiently eliminate mutant mitochondrial DNA without nuclear off-target ...
The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a pharmaceutical company ...
IRVINE, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback